The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as The post Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial appeared first on Pharmaceutical Business review.

In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves. The post Boehringer Ingelheim, MD Anderson to jointly advance new cancer therapies appeared first on Pharmaceutical Business review.

CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10 percent intravenous immunoglobulin in the treatment of The post Kedrion Biopharma announces enrollment of first patient in CARES10 trial appeared first on Pharmaceutical Business review.

BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock. According to the terms of the Proposal, The post Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares appeared first on Pharmaceutical Business review.

Ascletis’ Clinical Development Shanghai Center is at the heart of Shanghai, located at Jing’an Kerry Centre near Nanjing West Road. The opening ceremony was held on Aug 11, The post Ascletis opens Clinical Development Shanghai Center appeared first on Pharmaceutical Business review.